| Linda Bresnahan, MD | |
|
2101 Shiloh Church Rd, Ste 202, Davidson, NC 28036-7601 | |
| (704) 439-3770 | |
| Not Available |
| Full Name | Linda Bresnahan |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 2101 Shiloh Church Rd, Davidson, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023097664 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 33950 (North Carolina) | Primary |
| Entity Name | Carolinas Physicians Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437607686 PECOS PAC ID: 3375449655 Enrollment ID: O20040115000819 |
News Archive
Reuters on a report from the Organisation for Economic Cooperation and Development: The increase in health spending is "piling pressure budgets already hit" by the recession and is "likely to continue rising as populations age, technology improves and public expectations grow. ... Given the urgent need to reduce their budget deficits, many OECD governments will have to make difficult choices to sustain their healthcare systems: curb the growth of public spending on health, cut spending in other areas, or raise taxes," according to the report.
Endocannabinoids, signaling molecules produced in the body that share features with chemicals found in marijuana, can shut down genes needed for some pathogenic intestinal bacteria to colonize, multiply, and cause disease, new research led by UT Southwestern scientists shows.
The Washington Post examines how the "discovery of an almost untreatable form of tuberculosis [TB] in India has set off alarm bells around the world and helped spur a dramatic expansion of government efforts to battle the killer lung disease."
Trubion Pharmaceuticals, Inc. today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.
› Verified 9 days ago
| Entity Name | The Charlotte-mecklenburg Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669738829 PECOS PAC ID: 2961310685 Enrollment ID: O20100309000605 |
News Archive
Reuters on a report from the Organisation for Economic Cooperation and Development: The increase in health spending is "piling pressure budgets already hit" by the recession and is "likely to continue rising as populations age, technology improves and public expectations grow. ... Given the urgent need to reduce their budget deficits, many OECD governments will have to make difficult choices to sustain their healthcare systems: curb the growth of public spending on health, cut spending in other areas, or raise taxes," according to the report.
Endocannabinoids, signaling molecules produced in the body that share features with chemicals found in marijuana, can shut down genes needed for some pathogenic intestinal bacteria to colonize, multiply, and cause disease, new research led by UT Southwestern scientists shows.
The Washington Post examines how the "discovery of an almost untreatable form of tuberculosis [TB] in India has set off alarm bells around the world and helped spur a dramatic expansion of government efforts to battle the killer lung disease."
Trubion Pharmaceuticals, Inc. today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Linda Bresnahan, MD Po Box 19305, Charlotte, NC 28219-9305 Ph: () - | Linda Bresnahan, MD 2101 Shiloh Church Rd, Ste 202, Davidson, NC 28036-7601 Ph: (704) 439-3770 |
News Archive
Reuters on a report from the Organisation for Economic Cooperation and Development: The increase in health spending is "piling pressure budgets already hit" by the recession and is "likely to continue rising as populations age, technology improves and public expectations grow. ... Given the urgent need to reduce their budget deficits, many OECD governments will have to make difficult choices to sustain their healthcare systems: curb the growth of public spending on health, cut spending in other areas, or raise taxes," according to the report.
Endocannabinoids, signaling molecules produced in the body that share features with chemicals found in marijuana, can shut down genes needed for some pathogenic intestinal bacteria to colonize, multiply, and cause disease, new research led by UT Southwestern scientists shows.
The Washington Post examines how the "discovery of an almost untreatable form of tuberculosis [TB] in India has set off alarm bells around the world and helped spur a dramatic expansion of government efforts to battle the killer lung disease."
Trubion Pharmaceuticals, Inc. today announced Pfizer's decision to discontinue development of TRU-015 (PF-05212374), an investigational drug in Phase 2 evaluation for the treatment of rheumatoid arthritis (RA) developed under the companies' CD20 collaboration. However, Pfizer has confirmed that it will continue to develop SBI-087 (PF-05230895), Trubion's next-generation, humanized, subcutaneous CD20 RA product candidate also in Phase 2 clinical evaluation.
› Verified 9 days ago
Hannah Hughes Ehasz, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2101 Shiloh Church Rd, Ste 202, Davidson, NC 28036 Phone: 704-403-7800 | |
Ariel Catherine Haddad, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2101 Shiloh Church Rd, Ste 202, Davidson, NC 28036 Phone: 704-403-7800 |